CA2505633A1 - Antigen pipa and antibodies that bind thereto - Google Patents

Antigen pipa and antibodies that bind thereto Download PDF

Info

Publication number
CA2505633A1
CA2505633A1 CA002505633A CA2505633A CA2505633A1 CA 2505633 A1 CA2505633 A1 CA 2505633A1 CA 002505633 A CA002505633 A CA 002505633A CA 2505633 A CA2505633 A CA 2505633A CA 2505633 A1 CA2505633 A1 CA 2505633A1
Authority
CA
Canada
Prior art keywords
cancer
pipa
antibody
tumors
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002505633A
Other languages
English (en)
French (fr)
Inventor
Jennie P. Mather
Ronghao Li
Tony W. Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raven Biotechnologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2505633A1 publication Critical patent/CA2505633A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002505633A 2002-11-13 2003-11-13 Antigen pipa and antibodies that bind thereto Abandoned CA2505633A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42619202P 2002-11-13 2002-11-13
US60/426,192 2002-11-13
PCT/US2003/036134 WO2004043239A2 (en) 2002-11-13 2003-11-13 Antigen pipa and antibodies that bind thereto

Publications (1)

Publication Number Publication Date
CA2505633A1 true CA2505633A1 (en) 2004-05-27

Family

ID=32313118

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002505633A Abandoned CA2505633A1 (en) 2002-11-13 2003-11-13 Antigen pipa and antibodies that bind thereto

Country Status (6)

Country Link
US (1) US7405061B2 (enExample)
EP (1) EP1581096A4 (enExample)
JP (1) JP4757493B2 (enExample)
AU (1) AU2003295474B2 (enExample)
CA (1) CA2505633A1 (enExample)
WO (1) WO2004043239A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043239A2 (en) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
JP5328155B2 (ja) 2005-02-02 2013-10-30 マクロジェニックス ウエスト， インコーポレイテッド Ａｄａｍ−９モジュレータ
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
US20140315975A1 (en) 2011-06-21 2014-10-23 Nitto Denko Corporation Apoptosis-inducing agent
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
JP6727765B2 (ja) 2014-06-17 2020-07-22 日東電工株式会社 アポトーシス誘導剤
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5496550A (en) 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
IL86832A (en) 1987-06-22 2002-09-12 Medeva Holdings Bv A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
DE69333627T2 (de) 1993-01-14 2005-09-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Rekombinanter anti-hiv antikörper und seine herstellung
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU2077197A (en) 1996-03-18 1997-10-10 Novo Nordisk Biotech, Inc. Polypeptides having phytase activity and nucleic acids encoding same
WO1997035614A1 (en) * 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
EP0878541A4 (en) 1996-10-18 2001-10-17 Univ Osaka Res Found ROTAVIRUS ANTIGENS, VACCINALS AND MEDICATIONS AGAINST INFECTION BY ROTAVIRUS, AND METHOD FOR THEIR PRODUCTION
DE29803477U1 (de) * 1998-03-03 1998-07-09 P.E.R. Flucht- und Rettungsleitsysteme GmbH, 22885 Barsbüttel Vorrichtung zur Ausbildung aktiv leuchtender Leuchtwegesysteme
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2004043239A2 (en) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto

Also Published As

Publication number Publication date
WO2004043239A2 (en) 2004-05-27
WO2004043239A3 (en) 2005-09-29
AU2003295474A1 (en) 2004-06-03
AU2003295474B2 (en) 2009-07-30
US7405061B2 (en) 2008-07-29
JP2006506071A (ja) 2006-02-23
EP1581096A4 (en) 2006-06-21
EP1581096A2 (en) 2005-10-05
JP4757493B2 (ja) 2011-08-24
US20040171814A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
US7718774B2 (en) TES7 and antibodies that bind thereto
US8440197B2 (en) KID3 and KID3 antibodies that bind thereto
AU2003295474B2 (en) Antigen PIPA and antibodies that bind thereto
US20110045006A1 (en) LUCA2 and Antibodies That Bind Thereto
US20060171952A1 (en) JAM-3 and antibodies that bind thereto
CA2597171A1 (en) Antibodies to oncostatin m receptor
EP1841794A2 (en) Adam-9 modulators
JP2006506071A5 (enExample)
US7687242B2 (en) KID31 and antibodies that bind thereto
HK1086284B (en) Kid3 and anti-kid3 antibodies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131113